New drugs under clinical evaluation in the United States.
D000447:Aldehydes / Q000627:therapeutic use; D006585:Altretamine / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003961:Dianhydrogalactitol / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008453:Maytansine / Q000627:therapeutic use; D013311:Streptozocin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005641:Tegafur / Q000627:therapeutic use; D014255:Trichothecenes / Q000627:therapeutic use
D000447:Aldehydes; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D014255:Trichothecenes; D008453:Maytansine; D005641:Tegafur; D003961:Dianhydrogalactitol; D013311:Streptozocin; D002945:Cisplatin; D006585:Altretamine; D002330:Carmustine; D007069:Ifosfamide